Anti-Human VEGF (Clone 26503)
| Code | Size | Price |
|---|
| LEI-V103-25ug | 25 ug | £420.00 |
Quantity:
| LEI-V103-100ug | 100 ug | £682.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Isotype: IgG2b
Antibody Clonality: Monoclonal
Antibody Clone: 26503
Regulatory Status: RUO
Target Species: Human
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Neutralisation
- Western Blot (WB)
Shipping:
Ambient
Storage:
The lyophilized antibody can be stored desiccated at -20°C to -70°C for up to twelve months. The reconstituted antibody can be stored for at least four weeks at 2-8°C. For long-term storage of the reconstituted antibody aseptically aliquot into working volumes and store at -20°C to -70°C in a manual defrost freezer. Avoid repeated freeze thaw cycles. No detectable loss of activity was observed after six months.
Further Information
Conjugate/Tag/Label:
Purified No Carrier Protein
Format:
This monoclonal antibody has been 0.2 um filtered and lyophilized from modified Dulbecco's phosphate buffered saline (1X PBS) pH 7.2 - 7.4 containing 5.0% w/v trehalose with no calcium, magnesium or preservatives present.
Formulation:
This monoclonal antibody has been 0.2 um filtered and lyophilized from modified Dulbecco's phosphate buffered saline (1X PBS) pH 7.2 - 7.4 containing 5.0% w/v trehalose with no calcium, magnesium or preservatives present.
Immunogen:
Purified Recombinant Human VEGF (>98%)
Long Description:
Vascular endothelial growth factor (VEGF), a potent proangiogenic cytokine is the key signal used by oxygen-hungry cells to promote growth of blood vessels. It binds to specialized receptors on the surfaces of endothelial cells and directs them to build new vessels.1,2 VEGF are crucial regulators of vascular development during embryogenesis (vasculogenesis) and blood-vessel formation in the adult (angiogenesis). Abnormal VEGF function is associated with inflammatory diseases including atherosclerosis, and hyperthyroidism.3,4,5,6
Target:
VEGF
References
1. Folkman, J. et al. (2008) FASEB J. 22: 3728
2. Goodsell, DS. et al. (2002) The Oncologist 7: 569
3. Mugishima, H. et al. (2006) J Atheroscler Thromb. 13: 130
4. Claesson-Welsh, L. et al. (2006) Exp Cell Res. 312: 549
5. Claesson-Welsh, L. et al. (1999) Trends Biochem Sci. 28: 488
6. Ellis, LM. et al. (2005) J Clin Oncol. 23: 1011
Related Products
| Product Name | Product Code | Supplier | Anti-Mouse VEGF | LEI-V104 | Leinco Technologies | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anti-Human VEGF - Biotin | LEI-V105 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-Mouse VEGF - Biotin | LEI-V106 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-Rat VEGF (Clone 123704) | LEI-V142 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-Rat VEGF | LEI-V149 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-Rat VEGF - Biotin | LEI-V160 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||